explore -WSS

explore

author：focus 2025-10-01 21:35:51 - browse：3

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Quicker fix for pulse oximeters urged during FDA public meeting

focus

WSS

Cybersecurity threat forces Lurie Children's to take systems offline

The most pressing bird flu mysteries scientists want answered

Anthony Fauci pushes back on GOP claims during Covid hearing

BD to buy Edwards patient monitoring unit for $4.2 billion

Sutter Health’s antitrust win overturned by appeals court

Biden administration opens offers in Medicare drug price negotiations

Wikipedia

explore

focus

New air purifier tech could be key to improving indoor air quality

What we need to know about Arena Bioworks

Trump demands the U.S. pay no more for drugs than other countries … again

CMS got Medicare Advantage quality rating wrong, judge rules

Hepatitis C has a cure — but many Americans still lack access to it

Novo Nordisk to expand supply of Wegovy for U.S. patients

Heart attack and stroke risk calculators need revising

Juul spent big to court Black leaders to promote its e

Affirmative action in medical school literally saved lives

ASCO Takeaways: Winners, snoozers, and the art of cancer care

explore

Illumina board agrees to spin off Grail, as divestment plans proceed

A new initiative will help leaders fight the next pandemic

FTC loses bid to block Novant's North Carolina hospital merger

Take antibiotics after sex, CDC recommends for certain risk groups

Even great ERs can’t make up for American health disparities

Some dementia cases could be undiagnosed liver disease

entertainment

focus

focus

explore